Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study Article

sustainable development goals

authors

publication date

  • 2017

webpage

published in

keywords

  • VEGFR inhibitor
  • antiangiogenics
  • blinded independent central review
  • crossover
  • rank-preserving structural failure time (RPSFT)

start page

  • 339

end page

  • 343

volume

  • 28

issue

  • 2